// App-Quantinova.ai

: Clinical Profile and Long-Term Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in a Real-World Setting: High Frequency of Anemia Despite Decreased Intravascular Hemolysis

Researchers

Presenter

  • Katharina Versmold

Principal Investigators

  • Ferras Alashkar

  • Carina Raiser

  • Richard Ofori-Asenso

  • Tao Xu

  • Yutong Liu

  • Pablo Katz

  • Aijing Shang

  • Alexander Roeth

Medical Centers

  • Genesis Research, Hoboken, NJ

  • Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany

  • Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

Locations

  • United States

  • United Kingdom

  • Switzerland

  • Germany

Companies

  • Feng Chi Biotech Cor

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Nephrology

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Male Sexual Dysfunction

  • Venous thrombosis

  • Dyspnea

  • Anemia

Biomarkers

  • Lactate

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

  • Immunol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved